Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people ...

There are improved cardiovascular outcomes associated with semaglutide therapy in patients with overweight or obesity without diabetes.

Semaglutide shows potential for weight loss in older adults without harming bone density, but longer studies are essential to ...

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 5, 2025 /PRNewswire/ -- Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, adding to ...

Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and real-world findings, a top company executive said on Tuesday, ...

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...

The authors conclude that early use of semaglutide may serve as an effective adjunctive strategy to mitigate the metabolic burden associated with SGAs. By intervening during the initial stages of ...

The MarketWatch News Department was not involved in the creation of this content. -- Post hoc analyses include data showing investigational oral semaglutide 25 mg use was associated with improvements ...